Pfizer's 6.4% Dividend Yield: Analysis of Sustainability and Pipeline Growth

Pfizer (NYSE: PFE) is currently attracting income-focused investors with a forward dividend yield of 6.4%, a figure elevated by the stock's recent volatility and the decline of its pandemic-era revenue streams. While high yields can sometimes signal an impending payout cut, current indicators suggest Pfizer's dividend program remains sustainable. The healthcare giant has seen its stock price recover significantly over the last 12 months, posting a 25% gain as the market looks past the collapse of coronavirus-related sales. This recovery is supported by the company's status as a blue-chip defensive play during periods of geopolitical tension. To offset the loss of exclusivity for key products, such as the anticoagulant Eliquis, Pfizer is aggressively expanding its late-stage pipeline. The company launched 11 pivotal studies in 2025 and intends to initiate another 20 in 2026 to rejuvenate its product lineup. Two primary candidates are driving growth optimism: PF'4404, an investigational cancer medicine capable of earning indications across multiple cancer types, and MET097i, a weight-management therapy. The latter showed promise in phase 2 studies, potentially offering once-monthly dosing and fewer adverse reactions than current market leaders. If these phase 3 trials yield positive results, Pfizer could see a significant valuation rerating. Given the company's history of boosting dividends over the last five years despite various challenges, the current payout appears intact as the firm navigates this transition period.